Journal
MOLECULAR PSYCHIATRY
Volume 26, Issue 10, Pages 5751-5765Publisher
SPRINGERNATURE
DOI: 10.1038/s41380-020-0776-7
Keywords
-
Funding
- NIH [R01 GM134363, DP1 DA041722, R01 AG056259, RF1 AG057409]
- Research Training Grant in Alzheimer's Disease
- NATIONAL INSTITUTE ON AGING [ZIAAG000936] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Early stages of human Alzheimer's disease (AD) show hyperexcitability in the brain, leading to extensive synapse loss and cognitive dysfunction, with no current disease-modifying therapy available. Utilizing human iPSC models may be a valuable tool for screening drugs to treat hyperexcitability and synaptic damage in AD, potentially increasing the chances of success in treatment.
Beginning at early stages, human Alzheimer's disease (AD) brains manifest hyperexcitability, contributing to subsequent extensive synapse loss, which has been linked to cognitive dysfunction. No current therapy for AD is disease-modifying. Part of the problem with AD drug discovery is that transgenic mouse models have been poor predictors of potential human treatment. While it is undoubtedly important to test drugs in these animal models, additional evidence for drug efficacy in a human context might improve our chances of success. Accordingly, in order to test drugs in a human context, we have developed a platform of physiological assays using patch-clamp electrophysiology, calcium imaging, and multielectrode array (MEA) experiments on human (h)iPSC-derived 2D cortical neuronal cultures and 3D cerebral organoids. We compare hiPSCs bearing familial AD mutations vs. their wild-type (WT) isogenic controls in order to characterize the aberrant electrical activity in such a human context. Here, we show that these AD neuronal cultures and organoids manifest increased spontaneous action potentials, slow oscillatory events (similar to 1 Hz), and hypersynchronous network activity. Importantly, the dual-allosteric NMDAR antagonist NitroSynapsin, but not the FDA-approved drug memantine, abrogated this hyperactivity. We propose a novel model of synaptic plasticity in which aberrant neural networks are rebalanced by NitroSynapsin. We propose that hiPSC models may be useful for screening drugs to treat hyperexcitability and related synaptic damage in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available